Daily Newsletter

27 September 2023

Daily Newsletter

27 September 2023

RelyMD expands its platform with mental health services

The partnership provides access to CuraLinc mental health professionals when RelyMD is used for medical visits.

September 26 2023

US-based telehealth provider RelyMD is collaborating with CuraLinc Healthcare in Chicago to offer mental health services on its platform, starting 1 October 2023.

The partnership provides access to CuraLinc mental health professionals when RelyMD is used for medical visits.

It will address issues such as depression, anxiety, addiction, and family or work problems, among others.

In addition, the alliance allows RelyMD to showcase the range of services it offers to employers and individuals in a market where healthcare costs are rising.

RelyMD technical operations director Phillip Ndowu said: “RelyMD is looking to be a go-to telehealth provider for medical and mental health care, both as a direct-to-consumer service and as a benefit offered by organisations.

“Telehealth is an effective and efficient alternative to traditional healthcare.

“It's easy, accessible, online, and available via mobile devices as well.

“Patients can access comprehensive care 24/7, with RelyMD doctors available any time of day in more than 30 states.”

RelyMD is a subsidiary of ApolloMD, a physician-owned clinical outsourcing company based in Atlanta, offering both medical and mental health care.

It provides telehealth services to businesses, schools, and universities, with a focus on making healthcare accessible through online and mobile platforms.

CuraLinc Healthcare specialises in mental health care and aims to engage employees in mental health services to create a healthier workforce.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Primarily due to COVID-19, the healthcare sector has witnessed an acceleration in digital transformation, which has improved efficiencies and enhanced patient outcomes. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close